EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudie

Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy Versus Intensity Modulated Radiation Therapy for Localized Prostate Cancer

Amy J Wisdom, Beow Y Yeap, Jeff M Michalski, Nora K Horick, Anthony L Zietman, John P Christodouleas, Sophia C Kamran, Rahul R Parikh, Neha Vapiwala, Stephen Mihalcik, David T Miyamoto, Jing Zeng und 8 weitere

International Journal of Radiation Oncology*Biology*Physics · 2025

DOI: 10.1016/j.ijrobp.2024.09.043 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von Amy J Wisdom und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: awisdom1@partners.o…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Proton Therapy, Radiotherapy, Intensity-Modulated. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Massachusetts General Hospital, U.S. Department of Defense, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Men with localized prostate cancer may receive either photon-based intensity modulated radiation therapy (IMRT) or proton beam therapy (PBT). The PARTIQoL trial (NCT01617161) demonstrates the feasibility of performing a large, multicenter phase 3 randomized trial comparing IMRT with PBT for localized prostate cancer. Here, we report baseline features of patients enrolled on this trial and present strategies to improve feasibility of other similar trials. METHODS AND MATERIALS: Patients with low- or intermediate-risk prostate cancer were randomly assigned to either PBT or IMRT with stratification by institution, age, use of rectal spacer, and fractionation schedule (conventional fractionation: 79.2 Gy in 44 fractions vs moderate hypofractionation: 70.0 Gy in 28 fractions). The primary endpoint is a change from baseline bowel health using the Expanded Prostate Index Composite score 24 months after radiation therapy. Secondary objectives include treatment-related differences in urinary and erectile functions, adverse events, and efficacy endpoints. RESULTS: Between July 2012 and November 2021, 450 patients were successfully accrued. Patients were randomly assigned to either PBT (N = 226) or to IMRT (N = 224); 13 were ineligible or withdrew before treatment. The median age of 437 analyzed patients was 68 years (range, 46-89 years). A total of 41% of patients had low-risk and 59% had intermediate-risk disease. In total, 49% of patients were treated with conventional fractionation and 51% with moderately hypofractionation. 48% of patients used a rectal spacer. For patients receiving PBT, pencil beam scanning was used in 48%. PBT and IMRT arms were balanced for baseline variables. CONCLUSIONS: Despite significant challenges, the PARTIQoL trial demonstrated that, with targeted recruitment approaches, multicenter collaboration, payer engagement, and protocol updates to incorporate contemporary techniques, it is feasible to perform a large phase 3 randomized clinical trial to assess whether PBT improves outcomes. We will separately report primary results and continue to monitor participants for longer follow-up and secondary endpoints.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProton TherapyRadiotherapy, Intensity-ModulatedHumansMaleAgedFeasibility StudiesMiddle AgedAged, 80 and overRadiation Dose HypofractionationDose Fractionation, Radiation

Autor:innen und Institutionen

  • Department Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: awisdom1@partners.org.
  • Department Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.
  • Department Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

Förderung

  • Massachusetts General Hospital
  • U.S. Department of Defense
  • National Institutes of Health
  • National Cancer Institute
  • Radiation Oncology Institute
  • Kuni Foundation
  • Prostate Cancer Foundation

Zitieren

APA

Wisdom, A. J., Yeap, B. Y., Michalski, J. M., Horick, N. K., Zietman, A. L., Christodouleas, J. P., Kamran, S. C., Parikh, R. R., Vapiwala, N., Mihalcik, S., Miyamoto, D. T., Zeng, J., Gay, H. A., Pisansky, T. M., Mishra, M. V., Spratt, D. E., Mendenhall, N. P., Soffen, E. M., Bekelman, J. E., & Efstathiou, J. A. (2025). Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy Versus Intensity Modulated Radiation Therapy for Localized Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2024.09.043

Vancouver

Wisdom AJ, Yeap BY, Michalski JM, Horick NK, Zietman AL, Christodouleas JP, et al. Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy Versus Intensity Modulated Radiation Therapy for Localized Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2024.09.043

BibTeX
@article{Wisdom2025,
  author = {Wisdom, Amy J and Yeap, Beow Y and Michalski, Jeff M and Horick, Nora K and Zietman, Anthony L and Christodouleas, John P and Kamran, Sophia C and Parikh, Rahul R and Vapiwala, Neha and Mihalcik, Stephen and Miyamoto, David T and Zeng, Jing and Gay, Hiram A and Pisansky, Thomas M and Mishra, Mark V and Spratt, Daniel E and Mendenhall, Nancy P and Soffen, Edward M and Bekelman, Justin E and Efstathiou, Jason A},
  title = {Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy Versus Intensity Modulated Radiation Therapy for Localized Prostate Cancer},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2025},
  doi = {10.1016/j.ijrobp.2024.09.043}
}
Kostenlos starten →